Key result
Machine learning model predicts 3-month MACE in Takotsubo syndrome with ~0.80 AUC.
Why the study?
There was a need to develop predictive models integrating clinical and echocardiographic markers for early risk stratification of adverse cardiovascular events in Takotsubo syndrome patients.
Cohort (n=450)
Yes
Effect estimate: AUC 0.80 (95% CI 0.73-0.86)
A machine learning model integrating four clinical and echocardiographic variables can effectively predict 3-month major adverse cardiovascular events in patients with Takotsubo syndrome.
ML models may aid early TTS risk stratification; hypothesis-generating and requires prospective validation before practice change.
BACKGROUND: The purpose of this study was to develop machine learning (ML) models that integrate clinical and echocardiographic markers to predict adverse cardiovascular events in patients with Takotsubo syndrome (TTS). METHODS: ML-based prediction models were developed on the basis of 2 retrospective data sets comprising 450 TTS patients (252 in an internal cohort and 198 in an external cohort). Baseline clinical characteristics included demographic characteristics, medical history, triggering factors, symptoms, and vital signs. All echocardiograms were performed within 24 hours of hospital admission. Feature selection and model development were performed using the random forest algorithm for prediction of 3-month major adverse cardiovascular events (MACE). Model performance was evaluated using area under the curve (AUC), calibration, sensitivity, and specificity. Model interpretability was evaluated using SHapley Additive exPlanations. RESULTS: The established ML models, which integrated key clinical and echocardiographic variables, demonstrated good discrimination for 3-month MACE prediction. The machine learning-based clinical-echocardiographic-4 model, which incorporated mitral valve inflow (E wave) deceleration time, systolic blood pressure, right ventricular fractional area change, and heart rate showed an AUC of 0.80 (95% confidence interval, 0.73-0.86) in the internal cohort and an AUC of 0.76 (95% confidence interval, 0.69-0.84) in the external cohort. Calibration analyses showed good agreement between predicted and observed risks internally and acceptable calibration externally. SHapley Additive exPlanations analysis highlighted the dominant contributions of key features to MACE prediction. Restricted cubic spline analyses identified clinically relevant thresholds for elevated MACE risk: deceleration time < 129.9 ms, systolic blood pressure < 125 mm Hg, right ventricular fractional area change < 34.7%, and heart rate > 93 beats per minute. CONCLUSIONS: ML-based clinical-echocardiographic prediction models showed prognostic value in early risk stratification in hospitalized TTS patients.
No takes yet. Share an insight, caveat, or question.
Dai et al. (2026) conducted a cohort in Takotsubo syndrome (n=450). Machine learning-based clinical-echocardiographic-4 model was evaluated on 3-month major adverse cardiovascular events (MACE) (AUC 0.80, 95% CI 0.73-0.86). A machine learning model integrating clinical and echocardiographic variables predicted 3-month MACE in Takotsubo syndrome with an AUC of 0.80 (95% CI 0.73-0.86) in the internal cohort.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: